Sareum Hldgs Plc

Sareum Holdings plc is a clinical-stage small molecule drug development company focused on discovering and developing therapeutics for cancer and autoimmune diseases. Its lead product, SDC-1801, is a TYK2/JAK1 inhibitor that has completed Phase 1 clinical trials for autoimmune diseases. It also develops SDC-1802, a preclinical-stage TYK2/JAK1 inhibitor for cancer and cancer-immunotherapy applications, and SRA737, a clinical-stage oral selective Chk1 inhibitor that has completed Phase II clinical trials and targets cancer cell replication and DNA damage repair mechanisms. The company has a strategic collaboration with Receptor.AI, launched in August 2025, to accelerate discovery and optimisation of BBB-permeable TYK2/JAK1 inhibitors, with completion of the initial stage expected in Q4 2025. Sareum Holdings plc was formerly known as Keepfast plc and changed its name to Sareum Holdings plc in July 2004; it was incorporated in 2004 and is headquartered in Cambridge, the United Kingdom.